McCormick & Company stock hits new 12-month low amid Unilever deal talks and analyst cuts

The McCormick & Company stock (ISIN: US5797802064) on NYSE reached a new 52-week low of $52.35, trading last at $53.27, as merger discussions with Unilever's food unit spark mixed analyst reactions. US investors eye potential growth from the deal against recent earnings misses and insider selling. ISIN: US5797802064

McCormick & Company stock plunged to a new 52-week low on the NYSE, hitting $52.35 and closing at $53.27, well below its 50-day moving average of around $64.87 and 200-day average near $66.00. This sharp decline comes amid ongoing discussions for a potential all-stock merger with Unilever's global food business, confirmed by both companies but with no deal assured. For US investors, the stock's weakness highlights both acquisition-driven upside potential and risks from recent earnings shortfalls, insider sales, and cautious analyst targets.

As of: 25.03.2026

By Elena Vargas, Consumer Staples Analyst: McCormick's spice empire faces pivotal merger talks that could reshape its market position in a challenging consumer environment.

Stock Hits 52-Week Low on NYSE Amid Weak Sentiment

The McCormick & Company stock (NYSE:MKC) set a fresh 12-month low at $52.35, with the last trade at $53.27 on the NYSE. This marks a significant drop from prior levels, trading far under its 50-day simple moving average of $64.87 and 200-day average of $66.00. The move reflects broader concerns over consumer staples demand, recent earnings disappointments, and uncertainty around a potential Unilever deal.

Trading opened around $54.18 recently, with a 52-week range spanning $52.63 low to $83.15 high. Institutional ownership remains high at about 79.7%, but recent insider selling adds pressure: directors sold 5,000 shares each in early February at prices near $67.92, totaling over $339,600 for one transaction. Overall, insiders offloaded 115,000 shares worth roughly $7.95 million in the past 90 days.

Analysts maintain a consensus 'Hold' rating, with a $73.30 average price target. Recent cuts include UBS to $59 from $67 (neutral), Barclays to $67 from $72 (equal weight), and Stifel to $65 from $71 (hold). More optimistic views persist, like Deutsche Bank buy at $75 and Bernstein at $87.

Unilever Merger Talks Drive Volatility

McCormick is in advanced discussions with Unilever for an all-stock deal involving Unilever's foods business via a tax-free Reverse Morris Trust structure. The Wall Street Journal reported the talks last week, with both firms confirming exploration but stressing no certainty of completion. Bernstein SocGen cut its target to $77 from $85 but kept Outperform, projecting 15% upside for McCormick shareholders in year one, rising to 26% by year three.

The scenario assumes acquisition at 11.0x multiple, with 8.5% sales in cost synergies. The combined entity might trade at 11.3x EBITDA initially, with net debt to EBITDA at 2.1x. Unilever could receive a special dividend, and McCormick might assume some debt. This could expand McCormick's portfolio in seasonings, sauces, and global foods, bolstering its position against private-label competition.

For consumer staples, such deals test integration risks but offer scale in pricing power and distribution. McCormick's brands like Lawry's, Zatarain's, and Frank's RedHot dominate US shelves, and Unilever's additions could enhance international reach.

Recent Earnings Miss Adds Pressure

McCormick's Q4 2025 results showed EPS of $0.86, missing estimates of $0.87, though revenue hit $1.85 billion versus $1.84 billion expected. Sales rose 2.9% year-over-year, with net margin at 11.54% and return on equity 14.27%. FY2026 guidance is 3.050-3.130 EPS, aligning with analyst 3.07 forecast.

Financial health includes a quick ratio of 0.28, current ratio 0.70, debt-to-equity 0.54, market cap $14.28 billion, PE 18.16, PEG 3.11, beta 0.58. These metrics signal stability but limited liquidity, typical for staples with steady demand. Higher costs contributed to the miss, prompting target cuts from TD Cowen to $75 and BofA holding Buy at $80.

In consumer staples, volume pressures from inflation-weary shoppers challenge pricing. McCormick's premium positioning helps, but private labels erode share. The Unilever deal could counter this via broader portfolio and synergies.

Analyst Views Split on Deal Potential

Consensus holds at 'Hold' with five Buys, seven Holds, one Sell. Bullish notes from Bernstein emphasize accretion, while bears cite execution risks and valuation. The stock's low beta of 0.58 appeals to defensive investors seeking stability amid volatility.

Institutional moves include ETC 6 Meridian Low Beta ETF adding 1,261 shares. Heavy ownership underscores confidence in dividends—raised 40 years straight. For US investors, yield and growth balance attract income portfolios.

Merger scrutiny will intensify on regulatory hurdles, antitrust in foods, and integration. Success could lift multiples; failure might deepen the trough near $52.63 52-week low.

Why US Investors Should Watch Closely

McCormick commands strong US market share in spices and flavors, integral to home cooking. The Unilever deal targets growth in sauces and meal kits, aligning with American preferences for convenience. US investors benefit from NYSE listing, dividends, and defensive traits in recessions.

With 79.7% institutional hold, liquidity suits retail. Beta 0.58 offers downside protection. Potential 15-26% accretion per Bernstein draws income-growth seekers. Monitor Q1 earnings for deal progress.

Key Risks and Open Questions

Deal failure could extend downside, with targets as low as $59. Earnings misses signal cost pressures; liquidity ratios lag peers. Insider selling raises flags, though routine.

Consumer shift to value brands threatens premiums. Antitrust review in US/EU adds uncertainty. Debt assumption dilutes if synergies lag. Volatility persists until clarity emerges.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.